Baylor College of Medicine hosted U.S. Rep. Sylvia Garcia (TX-29) for a check presentation. Photo courtesy of BCM

A new funding project that's a part of the Bipartisan Omnibus Appropriations Bill doled out over $10 million to health care institutions — and a Houston initiative is cashing in on a chunk of that funding.

Baylor College of Medicine and Harris Health’s long-COVID care clinics received $1.1 million from the the Congressional Community Project Funding program. U.S. Rep. Sylvia Garcia (TX-29) attended the check presentation of the funding, as did Harris Health CEO Dr. Esmaeil Porsa, BCM President, CEO, and Executive Dean Dr. Paul Klotman, and Regional Director of the U.S. Department of Health and Human Services Sima Ladjevardian.

Long-COVID symptoms, which are categorized by any level of severity of the disease, can affect organ systems such as the heart, lungs, or brain, and include persistent shortness of breath, brain fog or anxiety. BCM started post-COVID treatment initiatives in 2021.

The organization's long-COVID care facilities will be expanding to Harris Health’s Strawberry Clinic located in East Harris County in the 29th Congressional District. Baylor's Institute for Clinical and Translational Research experts will also work to develop, maintain, and analyze a COVID-19 database.

“Rep Garcia was instrumental in guiding this project through to its approval,” says Klotman in a news release. “She understands the health disparities of her district and the greater Houston community and spearheaded efforts for the BCM program’s inclusion in the Appropriations Bill.”

Garcia, according to the release, is responsible for spearheading the effort for nine Houston area community projects that are currently being funding.

"In my district we know we have a high rate of COVID and we know we will have a high long-COVID impact," says Rep. Garcia. "It is important to support care and research because it is impacting their quality of life and it is impacting their ability to work. The long-COVID treatment and research projects going on here at Baylor are some of the best. We are doing the work, we are doing the research, and we will continue to do it together."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.